RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has 'Reached An Inflection Point'

Recursion Pharmaceuticals Inc. (RXRX) shares soared 16% in Wednesday's pre-market trade after the company's fourth-quarter (Q4) results beat Wall Street expectations.

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

“Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value,” said Najat Khan, CEO & President of Recursion.

Retail sentiment on Stocktwits around Recursion Pharmaceuticals trended in the 'bullish' territory at the time of writing.

Get updates to this developing story directly on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

MENAFN25022026007385015968ID1110788097